165 related articles for article (PubMed ID: 31111641)
21. [Efficacy and safety of 14-day amoxicillin and furazolidone-based quadruple rescue regimen for eradication of Helicobacter pylori: a retrospective study].
Liu X; Cheng H; Gao W; Dong X; Hu F
Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(8):567-71. PubMed ID: 24762682
[TBL] [Abstract][Full Text] [Related]
22. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients.
Qasim A; Sebastian S; Thornton O; Dobson M; McLoughlin R; Buckley M; O'Connor H; O'Morain C
Aliment Pharmacol Ther; 2005 Jan; 21(1):91-6. PubMed ID: 15644050
[TBL] [Abstract][Full Text] [Related]
23. [Effect of furazolidone quadruple regimen plus dental plaque removal procedures as rescue treatment of refractory Helicobacter pylori infection].
Gao W; Hu FL; Wang XM
Zhonghua Yi Xue Za Zhi; 2011 Mar; 91(12):836-9. PubMed ID: 21600165
[TBL] [Abstract][Full Text] [Related]
24. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.
Treiber G; Ammon S; Malfertheiner P; Klotz U
Helicobacter; 2002 Aug; 7(4):225-31. PubMed ID: 12165029
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy.
Ebrahimi-Dariani N; Mirmomen S; Mansour-Ghanaei F; Noormohammadpoor P; Sotodehmanesh R; Haghpanah B; Bahrami H
Med Sci Monit; 2003 Aug; 9(8):PI105-8. PubMed ID: 12942042
[TBL] [Abstract][Full Text] [Related]
26. Application of furazolidone in Helicobacter pylori infection eradication.
Han YY; Li JY; Guan JL; Liu M; Li PY
J Dig Dis; 2024 Mar; 25(3):148-155. PubMed ID: 38624062
[TBL] [Abstract][Full Text] [Related]
27. Comparison of quadruple and triple Furazolidone containing regimens on eradication of helicobacter pylori.
Mokhtare M; Hosseini V; Tirgar Fakheri H; Maleki I; Taghvaei T; Valizadeh SM; Sardarian H; Agah S; Khalilian A
Med J Islam Repub Iran; 2015; 29():195. PubMed ID: 26157713
[TBL] [Abstract][Full Text] [Related]
28. Novel and Effective Therapeutic Regimens for
Hu Y; Zhu Y; Lu NH
Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
[No Abstract] [Full Text] [Related]
29. Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial.
Riahizadeh S; Malekzadeh R; Agah S; Zendehdel N; Sotoudehmanesh R; Ebrahimi-Dariani N; Pourshams A; Vahedi H; Mikaeli J; Khatibian M; Massarrat S
Helicobacter; 2010 Dec; 15(6):497-504. PubMed ID: 21073605
[TBL] [Abstract][Full Text] [Related]
30. Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran.
Mohammadi M; Attaran B; Malekzadeh R; Graham DY
Dig Dis Sci; 2017 Aug; 62(8):1890-1896. PubMed ID: 28577244
[TBL] [Abstract][Full Text] [Related]
31. Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection.
Liu A; Wang Y; Song Y; Du Y
Saudi J Gastroenterol; 2020; 26(2):78-83. PubMed ID: 32295932
[TBL] [Abstract][Full Text] [Related]
32. One-week versus two-week furazolidone-based quadruple therapy as the first-line treatment for Helicobacter pylori infection in Iran.
Daghaghzadeh H; Emami MH; Karimi S; Raeisi M
J Gastroenterol Hepatol; 2007 Sep; 22(9):1399-403. PubMed ID: 17645463
[TBL] [Abstract][Full Text] [Related]
33. Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease.
Ghadir MR; Shafaghi A; Iranikhah A; Pakdin A; Joukar F; Mansour-Ghanaei F
Turk J Gastroenterol; 2011 Feb; 22(1):1-5. PubMed ID: 21480103
[TBL] [Abstract][Full Text] [Related]
34. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication.
Fakheri H; Merat S; Hosseini V; Malekzadeh R
Aliment Pharmacol Ther; 2004 Jan; 19(1):89-93. PubMed ID: 14687170
[TBL] [Abstract][Full Text] [Related]
35. Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.
Liao XM; Nong GH; Chen MZ; Huang XP; Cong YY; Huang YY; Wu BH; Wei JQ
World J Gastroenterol; 2015 May; 21(20):6310-6. PubMed ID: 26034367
[TBL] [Abstract][Full Text] [Related]
36. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
37. High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week.
Xiao SD; Liu WZ; Hu PJ; Xia DH; Tytgat GN
Aliment Pharmacol Ther; 1999 Mar; 13(3):311-5. PubMed ID: 10102963
[TBL] [Abstract][Full Text] [Related]
38. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
39. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
40. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
